1
|
Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, Ullman K, Billington CJ, Kaka A, Sultan S, Wilt TJ. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med 2024. [PMID: 38639549 DOI: 10.7326/m23-1490] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/20/2024] Open
Abstract
BACKGROUND Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. PURPOSE To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM). DATA SOURCES MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023. STUDY SELECTION RCTs lasting at least 52 weeks that included at least 500 adults with T2DM receiving eligible medications and reported any outcomes of interest. DATA EXTRACTION Data were abstracted by 1 reviewer and verified by a second. Independent, dual assessments of risk of bias and certainty of evidence (CoE) were done. DATA SYNTHESIS A total of 130 publications from 84 RCTs were identified. CoE was appraised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria for direct, indirect, and network meta-analysis (NMA); the highest CoE was reported. Compared with usual care, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (high CoE) and major adverse cardiovascular events (MACE) (moderate to high CoE), SGLT2 inhibitors reduce progression of chronic kidney disease (CKD) and heart failure hospitalizations and GLP1 agonists reduce stroke (high CoE), and SGLT2 inhibitors reduce serious adverse events and severe hypoglycemia (high CoE). The threshold for minimally important differences, which was predefined with the American College of Physicians Clinical Guidelines Committee, was not met for these outcomes. Compared with usual care, insulin, tirzepatide, and DPP4 inhibitors do not reduce all-cause mortality (low to high CoE). Compared with insulin, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (low to moderate CoE). Compared with DPP4 inhibitors, GLP1 agonists reduce all-cause mortality (moderate CoE). Compared with DPP4 inhibitors and sulfonylurea (SU), SGLT2 inhibitors reduce MACE (moderate to high CoE). Compared with SU and insulin, SGLT2 inhibitors and GLP1 agonists reduce severe hypoglycemia (low to high CoE). LIMITATIONS Infrequent direct comparisons between drugs of interest; sparse data for NMA on most outcomes; possible incoherence due to differences in baseline patient characteristics and usual care; insufficient data on predefined subgroups, including demographic subgroups, patients with prior cardiovascular disease, and treatment-naive persons. CONCLUSION In adults with T2DM, SGLT2 inhibitors and GLP1 agonists (but not DPP4 inhibitors, insulin, or tirzepatide) reduce all-cause mortality and MACE compared with usual care. SGLT2 inhibitors reduce CKD progression and heart failure hospitalization and GLP1 agonists reduce stroke compared with usual care. Serious adverse events and severe hypoglycemia are less frequent with SGLT2 inhibitors and GLP1 agonists than with insulin or SU. PRIMARY FUNDING SOURCE American College of Physicians. (PROSPERO: CRD42022322129).
Collapse
Affiliation(s)
- Tyler Drake
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., C.J.B., A.K.)
| | - Adrienne Landsteiner
- Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (A.L., R.M., M.A., C.K., K.U.)
| | - Lisa Langsetmo
- Department of Medicine, University of Minnesota; Center for Care Delivery & Outcomes Research, VA Health Care System; and Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota (L.L.)
| | - Roderick MacDonald
- Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (A.L., R.M., M.A., C.K., K.U.)
| | - Maylen Anthony
- Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (A.L., R.M., M.A., C.K., K.U.)
| | - Caleb Kalinowski
- Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (A.L., R.M., M.A., C.K., K.U.)
| | - Kristen Ullman
- Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (A.L., R.M., M.A., C.K., K.U.)
| | - Charles J Billington
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., C.J.B., A.K.)
| | - Anjum Kaka
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., C.J.B., A.K.)
| | - Shahnaz Sultan
- Department of Medicine, University of Minnesota, and Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis, Minnesota (S.S.)
| | - Timothy J Wilt
- Department of Medicine, VA Health Care System; Department of Medicine, University of Minnesota; Center for Care Delivery & Outcomes Research, VA Health Care System; and Division of Health Policy & Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota (T.J.W.)
| |
Collapse
|
2
|
Schousboe JT, Landsteiner A, Drake T, Sultan S, Langsetmo L, Kaka A, Anthony M, Billington CJ, Kalinowski C, Ullman K, Wilt TJ. Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians. Ann Intern Med 2024. [PMID: 38639547 DOI: 10.7326/m23-1492] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/20/2024] Open
Abstract
BACKGROUND In the United States, costs of antidiabetes medications exceed $327 billion. PURPOSE To systematically review cost-effectiveness analyses (CEAs) of newer antidiabetes medications for type 2 diabetes. DATA SOURCES Bibliographic databases from 1 January 2010 through 13 July 2023, limited to English. STUDY SELECTION Nonindustry-funded CEAs, done from a U.S. perspective that estimated cost per quality-adjusted life-year (QALY) gained for newer antidiabetic medications. Two reviewers screened the literature; disagreements were resolved with a third reviewer. DATA EXTRACTION Cost-effectiveness analyses were reviewed for treatment comparisons, model inputs, and outcomes. Risk of bias (RoB) of the CEAs was assessed using Drummond criteria and certainty of evidence (CoE) was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluations). Certainty of evidence was determined using cost per QALY thresholds predetermined by the American College of Physicians Clinical Guidelines Committee; low (>$150 000), intermediate ($50 to $150 000), or high (<$50 000) value per QALY compared with the alternative. DATA SYNTHESIS Nine CEAs were eligible (2 low, 1 high, and 6 some concerns RoB), evaluating glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucose-dependent insulinotropic peptide agonist (GIP/GLP1a), and insulin. Comparators were metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and others. Compared with metformin, GLP1a and SGLT2i are low value as first-line therapy (high CoE) but may be of intermediate value when added to metformin or background therapy compared with adding nothing (low CoE). Insulin analogues may be similarly effective but more expensive than NPH insulin (low CoE). The GIP/GLP1a value is uncertain (insufficient CoE). LIMITATIONS Cost-effectiveness analyses varied in methodological approach, assumptions, and drug comparisons. Risk of bias and GRADE method for CEAs are not well established. CONCLUSION Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions. PRIMARY FUNDING SOURCE American College of Physicians. (PROSPERO: CRD42022382315).
Collapse
Affiliation(s)
- John T Schousboe
- Park Nicollet Clinic and HealthPartners Institute, Bloomington, and Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota (J.T.S.)
| | | | - Tyler Drake
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., A.K., C.J.B.)
| | - Shahnaz Sultan
- Department of Medicine, University of Minnesota, and Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, Minnesota (S.S.)
| | - Lisa Langsetmo
- Department of Medicine, University of Minnesota, Center for Care Delivery and Outcomes Research, VA Health Care System, and Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota (L.L.)
| | - Anjum Kaka
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., A.K., C.J.B.)
| | - Maylen Anthony
- Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, Minnesota (M.A., C.K., K.U.)
| | - Charles J Billington
- Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., A.K., C.J.B.)
| | - Caleb Kalinowski
- Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, Minnesota (M.A., C.K., K.U.)
| | - Kristen Ullman
- Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, Minnesota (M.A., C.K., K.U.)
| | - Timothy J Wilt
- Division of Health Policy and Management, School of Public Health, and Department of Medicine, University of Minnesota, Department of Medicine and Center for Care Delivery and Outcomes Research, VA Health Care System, Minneapolis, Minnesota (T.J.W.)
| |
Collapse
|
3
|
Davis MJ, Rypka KJ, Perron AK, Keilty J, Wils B, Levine J, Rezcallah AT, Solomon R, Goldfarb N, Kaka A. Angioinvasive Trichophyton rubrum associated necrotizing fasciitis in an immunocompromised patient. Clin Case Rep 2023; 11:e7718. [PMID: 37786455 PMCID: PMC10541569 DOI: 10.1002/ccr3.7718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 06/28/2023] [Accepted: 07/07/2023] [Indexed: 10/04/2023] Open
Abstract
Angioinvasive dermatophytosis with necrotizing fasciitis can be a rare complication in immunocompromised patients with early surgical debridement, 12 weeks of oral terbinafine, and reduction in immunosuppression being a viable management strategy.
Collapse
Affiliation(s)
- Michael J. Davis
- Minneapolis VA Health Care System – Department of Infectious Diseases and University of Minnesota – Department of Infectious DiseasesMinneapolisMinnesotaUSA
| | - Katelyn J. Rypka
- Minneapolis VA Health Care System – Department of Dermatology and University of Minnesota – Department of DermatologyMinneapolisMinnesotaUSA
| | | | - John Keilty
- University of Minnesota Medical SchoolMinneapolisMinnesotaUSA
| | - Benjamin Wils
- University of Minnesota Medical SchoolMinneapolisMinnesotaUSA
| | - Joshua Levine
- University of Minnesota Medical SchoolMinneapolisMinnesotaUSA
| | - Anthony T. Rezcallah
- Minneapolis VA Health Care System – Department of Surgery and University of Minnesota – Department of SurgeryMinneapolisMinnesotaUSA
| | - Robin Solomon
- Department of PathologyMinneapolis VA Health Care SystemMinneapolisMinnesotaUSA
| | - Noah Goldfarb
- Minneapolis VA Health Care System – Department of Dermatology and University of Minnesota – Department of DermatologyMinneapolisMinnesotaUSA
| | - Anjum Kaka
- Department of Infectious DiseasesMinneapolis VA Health Care SystemMinneapolisMinnesotaUSA
| |
Collapse
|
4
|
Greer N, Bart B, Billington CJ, Diem SJ, Ensrud KE, Kaka A, Klein M, Melzer AC, Reule S, Shaukat A, Sheets K, Starks J, Vardeny O, McKenzie L, Stroebel B, Macdonald R, Sowerby K, Duan-Porter W, Wilt TJ. COVID-19 postacute care major organ damage: a systematic review. BMJ Open 2022; 12:e061245. [PMID: 36002211 PMCID: PMC9412042 DOI: 10.1136/bmjopen-2022-061245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Major organ complications have been reported in patients hospitalised for COVID-19; most studies lacked controls. OBJECTIVE Examine major organ damage postdischarge among adults hospitalised for COVID-19 versus non-COVID-19 controls. DATA SOURCES MEDLINE, Embase and Cochrane Library from 1 January 2020 to 19 May 2021. STUDY ELIGIBILITY CRITERIA English language studies of adults discharged from hospital for COVID-19; reporting major organ damage. Single review of abstracts; independent dual review of full text. STUDY APPRAISAL AND SYNTHESIS METHODS Study quality was assessed using the Joanna Briggs Institute Appraisal Checklist for Cohort Studies. Outcome data were not pooled due to heterogeneity in populations, study designs and outcome assessment methods; findings are narratively synthesised. RESULTS Of 124 studies in a full evidence report, 9 included non-COVID controls and are described here. Four of the nine (three USA, one UK) used large administrative databases. Four of the remaining five studies enrolled <600 COVID-19 patients. Mean or median age ranged from 49 to 70 years with 46%-94% male and 48%-78% White race; 10%-40% had been in intensive care units. Follow-up ranged from 4 weeks to 22 weeks postdischarge. Four used hospitalised controls, three non-hospitalised controls and two were unclear. Studies used various definitions of, and methods to assess, major organ damage outcomes. While the magnitude of effect differed across studies, incident cardiac, pulmonary, liver, acute and chronic kidney, stroke, diabetes, and coagulation disorders were consistently greater in adults hospitalised for COVID-19 compared with non-COVID-19 controls. LIMITATIONS Applicability to subgroups (age, gender, COVID-19 severity, treatment, vaccination status) and non-hospitalised patients is unknown. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS Postacute COVID-19 major organ damage is common and likely higher than controls. However, there is substantial uncertainty. More consistent reporting of clinical outcomes and pre-COVID health status along with careful selection of control groups are needed to address evidence gaps. PROSPERO REGISTRATION NUMBER CRD42020204788.
Collapse
Affiliation(s)
- Nancy Greer
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Bradley Bart
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Division of Cardiology, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Charles J Billington
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Section of Endocrinology and Metabolism, Department of Medicine,Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Susan J Diem
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA
| | - Kristine E Ensrud
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA
| | - Anjum Kaka
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Section of Infectious Diseases, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Mark Klein
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Hematology/Oncology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Anne C Melzer
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Scott Reule
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Division of Nephrology, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Aasma Shaukat
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Division of Gastroenterology, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Kerry Sheets
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Division of Geriatrics, Hennepin Healthcare, Minneapolis, Minnesota, USA
| | - Jamie Starks
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Orly Vardeny
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- Department of Pharmacy, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Lauren McKenzie
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Benjamin Stroebel
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Roderick Macdonald
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Katie Sowerby
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Wei Duan-Porter
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Timothy J Wilt
- Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA
- Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA
| |
Collapse
|
5
|
Babcock CP, Pullen MF, Manivel JC, Yamanaka BM, Kaka A. A 66-Year-Old Man With Progressive Chest Pain, Dyspnea, and Incomplete Paraplegia of the Lower Extremities. Clin Infect Dis 2021; 70:2743-2746. [PMID: 32520329 DOI: 10.1093/cid/ciz870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Corey P Babcock
- University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Matthew F Pullen
- Division of Infectious Disease and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| | - Juan C Manivel
- Anatomic Pathology, Veterans Affairs Medical Center, and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota, USA
| | - Bradley M Yamanaka
- Section of Hospital Medicine, Veterans Affairs Medical Center, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| | - Anjum Kaka
- Section of Infectious Disease, Veterans Affairs Medical Center, and Division of Infectious Disease and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|
6
|
Kalhoro DH, Kalhoro MS, Mangi MH, Jahejo AR, Kumbhar S, Lochi GM, Mari GM, Kaka A, Lund AK, Liu YJ. Antimicrobial resistance of staphylococci and streptococci isolated from dogs. Trop Biomed 2019; 36:468-474. [PMID: 33597408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
A study was conducted for the examination of bacterial species isolated in dogs from Animal Clinics of Nanjing Agricultural University, China. Forty nasal swabs were taken from dogs having respiratory signs. Staphylococcus pseudintermedius was the most frequently isolated pathogen (37.50 %) followed by Staphylococcus aureus (18.75%), Streptococcus pluranimalium (10.93%), Streptococcus canis (9.37%), Staphylococcus schleiferi (9.37%), Staphylococcus intermedius (6.25%), Staphylococcus cohnii (4.71%) and Staphylococcus hominis (3.12%). S. pseudintermedius and S. pluranimalium were subjected to commonly used antibiotics for determination of resistant drugs. Antimicrobial resistance in S. pseudintermedius was common in gentamicin (70.83%) and tetracycline (50%) while in S. pluranimalium was common in enrofloxacin (71.42%) and gentamicin (57.14%).
Collapse
Affiliation(s)
- D H Kalhoro
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | - M S Kalhoro
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | - M H Mangi
- Laboratory of Animal Pathology and Public Health, Key Laboratory of Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agriculture University, Beijing, China
| | - A R Jahejo
- College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Taigu, China
| | - S Kumbhar
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | | | - G M Mari
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | - A Kaka
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | - A K Lund
- Faculty of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tandojam-70060, Pakistan
| | - Y J Liu
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
| |
Collapse
|
7
|
Fox T, Solomon R, Kaka A. Disseminated coccidioidomycosis. Postgrad Med J 2018; 94:722-723. [PMID: 29970388 DOI: 10.1136/postgradmedj-2017-135545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 06/07/2018] [Accepted: 06/14/2018] [Indexed: 11/04/2022]
Affiliation(s)
- Teresa Fox
- Department of Infectious Diseases, Minneapolis VA Health Care System, University of Minnesota, Minneapolis, Minnesota, USA
| | - Robin Solomon
- Department of Pathology, Minneapolis VA Health Care System, University of Minnesota, Minneapolis, Minnesota, USA
| | - Anjum Kaka
- Department of Infectious Diseases, Minneapolis VA Health Care System, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|
8
|
Alpern JD, Kaka A. Minocycline-induced skin hyperpigmentation. Postgrad Med J 2017; 93:572-573. [DOI: 10.1136/postgradmedj-2016-134782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Revised: 02/11/2017] [Accepted: 03/05/2017] [Indexed: 11/04/2022]
|
9
|
Kaka A, Wahid H, Rosnina Y, Yimer N, Khumran AM, Behan AA, Ebrahimi M. Alpha-Linolenic Acid Supplementation in Tris Extender Can Improve Frozen-Thawed Bull Semen Quality. Reprod Domest Anim 2014; 50:29-33. [DOI: 10.1111/rda.12445] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 09/21/2014] [Indexed: 11/27/2022]
Affiliation(s)
- A Kaka
- Department of Veterinary Clinical Studies; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
- Sindh Agriculture University; Tando jam Pakistan
| | - H Wahid
- Department of Veterinary Clinical Studies; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
| | - Y Rosnina
- Department of Veterinary Clinical Studies; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
| | - N Yimer
- Department of Veterinary Clinical Studies; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
| | - AM Khumran
- Department of Veterinary Clinical Studies; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
| | - AA Behan
- Department of Animal Science; Faculty of Agriculture; Universiti Putra Malaysia; Serdang Malaysia
| | - M Ebrahimi
- Department of Veterinary Preclinical Sciences; Faculty of Veterinary Medicine; Universiti Putra Malaysia; Serdang Malaysia
| |
Collapse
|
10
|
Affiliation(s)
- Monica Rani
- University of Minnesota, Minneapolis, MN, USA.
| | | |
Collapse
|
11
|
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, Luchman A, Kelly JJ, Weiss S, Hamilton MG, Cairncross G, Senger DL, Bell J, McFadden G, Forsyth PA, Tzeng SY, Guerrero-Cazares H, Martinez EE, Young NP, Sunshine JC, Quinones-Hinojosa A, Green JJ, Lei L, D'Amico R, Sisti J, Leung R, Sonabend AM, Guarnieri P, Rosenfeld SS, Bruce JN, Canoll P, Baichwal VR, Reeves L, Chad BL, Zavitz KH, Beelen AP, Mather GG, Carlson RO, Manton C, Chandra J, Keir ST, Reardon DA, Saling JR, Gray LS, Bigner DD, Friedman HS, Zhang J, Brun J, Ogbomo H, Zemp F, Wang Z, Stojdl DJ, Lun X, Forsyth PA, Kong LY, Hatiboglu MA, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB, Amendolara B, Gil O, Lei L, Ivkovic S, Bruce J, Canoll P, Rosenfeld S, Finniss S, Perlstein B, Miller C, Okhrimenko H, Kazimirsky G, Cazacu S, Lemke N, Brodie S, Rempel SA, Rosenblum M, Mikkelsen T, Margel S, Brodie C, Guvenc H, Demir H, Gupta S, Mazumder S, Ray-Chaundhury A, Li T, Li C, Nakano I, Rahman R, Rahman C, Smith S, Macarthur D, Rose F, Shakesheff K, Grundy RG, Brenner AJ, Goins B, Bao A, Miller J, Trevino A, Zuniga R, Phillips WT, Gilg AG, Bowers KG, Toole BP, Maria BL, Leung GK, Sun S, Wong ST, Zhang XQ, Pu JK, Lui WM, Marino AM, Hussaini IM, Amos S, Simpson K, Redpath GT, Lyons C, Dipierro C, Grant GA, Wilson C, Salami S, Macaroni P, Li S, Park JY, Needham D, Bigner D, Dewhirst M, Ohlfest J, Gallardo J, Argawal S, Mittapalli R, Donelson R, Elmquist WF, Nicolaides T, Hariono S, Barkovich K, Hashizume R, Rowitch D, Weiss W, Sheer D, Baker S, Paugh B, Waldman T, Li H, Jones C, Forshew T, James D, Caroline H, Patrick R, Katrin L, Karl F, Ghazaleh T, Michael W, Albrecht V, Thorsteinsdottir J, Wagner E, Tonn JC, Ogris M, Schichor C, Charest G, Paquette B, Sanche L, Mathieu D, Fortin D, Qi X, Cuttitta F, Chu Z, Celerier J, Pakradouni J, Rixe O, Hashizume R, Gragg A, Muller S, Banerjee A, Phillips J, Prados M, Haas-Kogan D, Gupta N, James D, Florence L, Gwendoline VG, Veronique M, Robert K, Agarwal S, Mittapalli RK, Cen L, Carlson BL, Elmquist WF, Sarkaria JN, Sengupta S, Weeraratne SD, Rallapalli S, Amani V, Pierre-Francois J, Teider N, Rotenberg A, Cook J, Pomeroy SL, Jenses F, Cho YJ, Hjouj M, Last D, Guez D, Daniels D, Lavee J, Rubinsky B, Mardor Y, Serwer LP, Noble CO, Michaud K, Drummond DC, Ozawa T, Zhou Y, Marks JD, Bankiewicz K, Park JW, James D, Wang W, Cho H, Weintraub M, Jhaveri N, Torres S, Petasis N, Schonthal AH, Louie SG, Hofman FM, Chen TC, Grada Z, Hegde M, Schaffer DR, Ghazi A, Byrd T, Dotti G, Wels W, Heslop HE, Gottschalk S, Baker M, Ahmed N, Hamblett KJ, Kozlosky CJ, Liu H, Siu S, Arora T, Retter MW, Matsuda K, Hill JS, Fanslow WC, Diaz RJ, Etame A, Meaghan O, Mainprize T, Smith C, Hynynen K, Rutka J, Pradarelli J, Yoo JY, Kaka A, Alvarez-Breckenridge C, Pan Q, Chiocca EA, Teknos T, Kaur B, Lee SY, Slagle-Webb B, Sheehan JM, Connor JR, Cote J, Lepage M, Gobeil F, Fortin D, Kleijn A, Balvers R, Kloezeman J, Dirven C, Lamfers M, Leenstra S, See W, Tan IL, Nicolaides T, Pieper R, Jiang H, White E, Rios-Vicil CI, Yung WKA, Gomez-Manzano C, Fueyo J, Zemp FJ, McKenzie BA, Lun X, McFadden G, Forsyth PA, Mueller S, Yang X, Hashizume R, Gragg A, Smirnov I, Prados M, James DC, Phillips JJ, Berger MS, Rowitch DH, Gupta N, Haas-Kogan DH, D'Amico R, Lei L, Kennedy B, Rosenfeld SS, Canoll P, Bruce JN, Gopalakrishnan V, Das C, Taylor P, Kommagani R, Su X, Aguilera D, Thomas A, Wolff J, Flores E, Kadakia M, Alkins R, Broderson P, Sodhi R, Hynynen K, Chung SA, McDonald KL, Shen H, Day BW, Stringer BW, Johns T, Decollogne S, Teo C, Hogg PJ, Dilda PJ, Patel TR, Zhou J, Piepmeier JM, Saltzman WM, Vogelbaum MA, Agarwal S, Manchanda P, Ohlfest JR, Elmquist WF, Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Sarkaria JN, Ogbomo H, Lun X, Zhang J, McFadden G, Mody C, Forsyth P, Dasgupta T, Yang X, Hashizume R, Gragg A, Prados M, Nicolaides T, James CD, Haas-Kogan D, Madhankumar AB, Webb BS, Park A, Harbaugh K, Sheehan J, Connor JR. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Jensen RL, Gilliespie D, Ajewung N, Faure R, Kamnasaran D, Ajewung N, Poirier D, Kamnasaran D, Tamura K, Wakimoto H, Rabkin SD, Martuza RL, Shah K, Hashizume R, Aoki Y, Serwer LP, Drummond D, Noble C, Park J, Bankiewicz K, James DC, Gupta N, Agerholm-Larsen B, Iversen HK, Jensen KS, Moller J, Ibsen P, Mahmood F, Gehl J, Corem E, Ram Z, Daniels D, Last D, Shneor R, Salomon S, Perlstein B, Margel S, Mardor Y, Charest G, Fortin D, Mathieu D, Sanche L, Paquette B, Li HF, Hashizume R, Aoki Y, Hariono S, Dasgupta T, Kim JS, Haas-Kogan D, Weiss WA, Gupta N, James CD, Waldman T, Nicolaides T, Ozawa T, Rao S, Sun H, Ng C, De La Torre J, Santos R, Prados M, James CD, Butowski N, Michaud K, Solomon DA, Li HF, Kim JS, Prados MD, Ozawa T, Waldman T, James CD, Pandya H, Gibo D, Debinski W, Vinchon-Petit S, Jarnet D, Jadaud E, Feuvret L, Garcion E, Menei P, Chen R, Yu JC, Liu C, Jaffer ZM, Chabala JC, Winssinger N, Rubenstein AE, Emdad L, Kothari H, Qadeer Z, Binello E, Germano I, Hirschberg H, Baek SK, Kwon YJ, Sun CH, Li SC, Madsen S, Debinski W, Liu T, Wang SW, Gibo DM, Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Houseman BT, Nicolaides T, James CD, Haas-Kogan D, Oakes SA, Debnath J, Shokat KM, Weiss WA, Sai K, Chen F, Qiu Z, Mou Y, Zhang X, Yang Q, Chen Z, Patel TR, Zhou J, Piepmeier JM, Saltzman WM, Banerjee S, Kaul A, Gianino SM, Christians U, Gutmann DH, Wu J, Shen R, Puduvalli V, Koul D, Alfred Yung WK, Yun J, Sonabend A, Stuart M, Yanagihara T, Dashnaw S, Brown T, McCormick P, Romanov A, Sebastian M, Canoll P, Bruce JN, Piao L, Joshi K, Lee RJ, Nakano I, Madsen SJ, Chou CC, Blickenstaff JW, Sun CH, Zhou YH, Hirschberg H, Tome CML, Wykosky J, Palma E, Debinski W, Nduom E, Machaidze R, Kaluzova M, Wang Y, Nie S, Hadjipanayis C, Saito R, Nakamura T, Sonoda Y, Kumabe T, Tominaga T, Lun X, Zemp F, Zhou H, Stechishin O, Kelly JJ, Weiss S, Hamilton MG, Cairncross G, Rabinovich BA, Bell J, McFadden G, Senger DL, Forsyth PA, Kang P, Jane EP, Premkumar DR, Pollack IF, Yoo JY, Haseley A, Bratasz A, Powell K, Chiocca EA, Kaur B, Johns TG, Ferruzzi P, Mennillo F, De Rosa A, Rossi M, Giordano C, Magrini R, Benedetti G, Pericot GL, Magnoni L, Mori E, Thomas R, Tunici P, Bakker A, Yoo JY, Pradarelli J, Kaka A, Alvarez-Breckenridge C, Pan Q, Teknos T, Chiocca EA, Kaur B, Cen L, Ostrem JL, Schroeder MA, Mladek AC, Fink SR, Jenkins RB, Sarkaria JN, Madhankumar AB, Slagle-Webb B, Park A, Pang M, Klinger M, Harbaugh KS, Sheehan JM, Connor JR, Chen TC, Wang W, Hofman FM, Serwer LP, Michaud K, Drummond DC, Noble CO, Park JW, Ozawa T, James CD, Serwer LP, Noble CO, Michaud K, Drummond DC, Ozawa T, Zhou Y, Marks JD, Bankiewicz K, Park JW, James CD, Alonso MM, Gomez-Manzano C, Cortes-Santiago N, Roche FP, Fueyo J, Johannessen TCA, Grudic A, Tysnes BB, Nigro J, Bjerkvig R, Joshi AD, Parsons W, Velculescu VE, Riggins GJ, Bindra RS, Jasin M, Powell SN, Fu J, Koul D, Shen RJ, Colman H, Lang FF, Jensen MR, Alfred Yung WK, Friedman GK, Haas M, Cassady KA, Gillespie GY, Nguyen V, Murphy LT, Beauchamp AS, Hollingsworth CK, Debinski W, Mintz A, Pandya H, Garg S, Gibo D, Kridel S, Debinski W, Conrad CA, Madden T, Ji Y, Colman H, Priebe W, Seleverstov O, Purow BW, Grant GA, Wilson C, Campbell M, Humphries P, Li S, Li J, Johnson A, Bigner D, Dewhirst M, Sarkaria JN, Cen L, Pokorny JL, Mladek AC, Kitange GJ, Schroeder MA, Carlson BL, Suphangul M, Petro B, Mukhtar L, Baig MS, Villano J, Mahmud N, Keir ST, Reardon DA, Watson M, Shore GC, Bigner DD, Friedman HS, Keir ST, Gururangan S, Reardon DA, Bigner DD, Friedman HS. Pre-clinical Experimental Therapeutics and Pharmacology. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|